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ABSTRACT
Background Clinical classiﬁcation of rare sequence
changes identiﬁed in the breast cancer susceptibility
genes BRCA1 and BRCA2 is essential for appropriate
genetic counselling of individuals carrying these variants.
We previously showed that variant BRCA1 c.5096G>A p.
Arg1699Gln in the BRCA1 transcriptional transactivation
domain demonstrated equivocal results from a series
of functional assays, and proposed that this variant
may confer low to moderate risk of cancer.
Methods Measures of genetic risk (report of family
history, segregation) were assessed for 68 BRCA1
c.5096G>A p.Arg1699Gln (R1699Q) families recruited
through family cancer clinics, comparing results with
34 families carrying the previously classiﬁed pathogenic
BRCA1 c.5095C>T p.Arg1699Trp (R1699W) mutation at
the same residue, and to 243 breast cancer families with
no BRCA1 pathogenic mutation (BRCA-X).
Results Comparison of BRCA1 carrier prediction scores
of probands using the BOADICEA risk prediction tool
revealed that BRCA1 c.5096G>A p.Arg1699Gln variant
carriers had family histories that were less ‘BRCA1-like’
than BRCA1 c.5095C>T p.Arg1699Trp mutation carriers
(p<0.00001), but more ‘BRCA1-like’ than BRCA-X
families (p=0.0004). Further, modiﬁed segregation
analysis of the subset of 30 families with additional
genotyping showed that BRCA1 c.5096G >A p.
Arg1699Gln had reduced penetrance compared with the
average truncating BRCA1 mutation penetrance
(p=0.0002), with estimated cumulative risks to age 70
of breast or ovarian cancer of 24%.
Conclusions Our results provide substantial evidence
that the BRCA1 c.5096G>A p.Arg1699Gln (R1699Q)
variant, demonstrating ambiguous functional deﬁciency
across multiple assays, is associated with
intermediate risk of breast and ovarian cancer,
highlighting challenges for risk modelling and clinical
management of patients of this and other potential
moderate-risk variants.
INTRODUCTION
The clinical classiﬁcation of rare sequence changes
identiﬁed in the high-risk breast cancer susceptibil-
ity genes BRCA1 and BRCA2 is essential for appro-
priate genetic counselling of individuals carrying
these variants. Classiﬁcation of BRCA1 and BRCA2
variants was facilitated by the development of a
multifactorial likelihood model,1 which provides a
quantitative estimate of pathogenicity by assessing
measures of genetic and other features of variant
carriers relative to characteristics observed for clas-
sical high-risk mutations. Moreover, this quantita-
tive assessment of risk has been linked to clinical
management guidelines to provide a basis for stan-
dardised variant reporting, variant classiﬁcation
and management of families with such variants.2
The multifactorial likelihood methodology has
been applied in multiple studies,1 3–15 with more
than 200 BRCA1 or BRCA2 variants now classiﬁed
using this approach.16 However, the multifactorial
approach is designed to distinguish high-risk muta-
tions from variants with no or little clinical signiﬁ-
cance, and it is likely that additional methods are
required to detect and validate BRCA1 or BRCA2
rare variants associated with more modest risks
than the average penetrance reported for classical
mutations in these genes, that is, 65% risk of
breast cancer and 39% risk of ovarian cancer to age
70 years for BRCA1 mutations, and 45% risk of
breast cancer and 11% risk of ovarian cancer to age
70 years for BRCA2 mutations.17
We previously showed that the variant BRCA1
R1699Q (c.5096G>A p.Arg1699Gln) located in the
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BRCA1 carboxyl terminal (BRCT) regions of the transcriptional
transactivation domain (TAD) demonstrated equivocal results
from a series of functional assays, when compared with wild-
type control and known pathogenic missense mutation BRCA1
A1708E (c.5123C>A p.Ala1708Glu) which was null in all
assays.8 In particular, this variant displayed intermediate tran-
scriptional transactivation activity in human 293T and T47D
cell lines and wild-type centrosome ampliﬁcation function, but
behaved as a deleterious mutation when assayed for formation
of nuclear foci and trypsin sensitivity. There is also inconsist-
ency in assay results from other functional studies, including
discrepancies between yeast and mammalian transcriptional
transactivation assay results in a single report,18 and categorisa-
tion of R1699Q as a variant with strong functional effect due
to compromised peptide binding activity and speciﬁcity, and
compromised transcriptional activity in yet another study.19
Most recently, Chang et al20 performed an extensive study of
the R1699Q substitution using mouse embryonic stem (ES)
cell-based functional assays, and demonstrated that this variant
affected mouse ES cell survival and differentiation, and was
unable to rescue embryonic lethality of Brca1-null mice.
However, this study also demonstrated that the variant did not
cause signiﬁcant cell-cycle defects, and had no effect on
genomic stability, but it was suggested that abrogated repres-
sion of oncomir miR-155 was the underlying mechanism for
BRCA1-mediated tumour suppression. The equivocal behaviour
of this variant can be explained at a protein level, as demon-
strated by protein modelling predictions shown in
supplementary ﬁgure S1. R1699 is located in the linker connect-
ing the BRCT repeat domain, and participates in a salt bridge
between the BRCT repeats.21 The loss of salt-bridging interac-
tions and steric strain associated with accommodating a trypto-
phan substitution contributes to conformational instability of
the R1699W (c.5095C>T p.Arg1699Trp) pathogenic mutation
and, subsequently, disrupts transcriptional transactivation func-
tion. By contrast, substitutions with little or no effect on struc-
tures, such as R1699Q, may be fully or partially active in these
assays. Moreover, R1699 lies in a conserved phosphopeptide-
binding groove of the BRCA1 repeat, and plays an important
role in phosphopeptide recognition through its interaction.
Speciﬁcally, our protein modelling results directly comparing
R1699Q and R1699W show that the volume of R1699W is
likely to cause steric clashes with the phosphopeptide,
whereas, the smaller surface and volume presentation of
R1699Q will not cause steric clashes, but may modestly alter
phosphopeptide recognition (see supplementary ﬁgure S1).
These modelling predictions explain the experimental results
from biophysical assays of BACH1 binding afﬁnity which
demonstrated that R1699W leads to a signiﬁcant 160-fold
reduction in afﬁnity compared with wild-type, whereas, the
reduction is only 24-fold for R1699Q.22
We previously proposed that the R1699Q variant has partial
abrogation of BRCA1 functions, and may confer low to mod-
erate risk of cancer that would be better measured using
pooled family studies.8 In a study assessing pathogenicity of
1433 variants based on family history, co-occurrence and cose-
gregation data from a large dataset derived from clinical
testing at Myriad Genetic Laboratories, the combined odds
that BRCA1 R1699Q was a pathogenic variant compared with
neutral/no clinical signiﬁcance was 2.5:1, based on a sample of
16 family histories with cosegregation data on only three of
these.11 By contrast, BRCA1 R1699W at the same residue was
classiﬁed as pathogenic, with odds in favour of pathogenicity
of 39 978:1.11 Bioinformatic analysis shows that the arginine
at position 1699 is conserved through tunicate, but the sever-
ity of the amino acid substitution is much less marked for glu-
tamine (Grantham deviation 43) compared with tryptophan
(Grantham deviation 101). Accordingly, the Align-GVGD algo-
rithm (http://brca.iarc.fr) classiﬁes R1699Q as a C35, while
R1699W falls in the most severe C65 category for missense
alterations. Based on an analysis of the same Myriad dataset,
C35 variants were estimated to have a prior probability of
pathogenicity of 0.66, while C65 variants were associated
with a prior probability of 0.81.11 23
Mohammadi et al24 assessed the likelihood of causality by
cosegregation analysis of a single family, and reported a likeli-
hood ratio (LR) of 1.4 for R1699Q. In another genetic study of
several BRCA1/2 sequence variants, Gomez Garcia et al25 exam-
ined the R1699Q and R1699W variants as part of a model-
building exercise that incorporated family history, and esti-
mated the probability of pathogenicity to be 0.87 for R1699Q
and >0.99 for R1699W. Although this model classiﬁed both
variants as pathogenic mutations, the authors noted that
R1699Q did not cosegregate completely with disease in one of
three of the families in which such data were available.
In summary, a number of different studies to date indicate
that the R1699Q variant demonstrates inconsistent or incon-
clusive results at the functional and genetic level. In an exten-
sion of our previous study,8 we conﬁrmed the intermediate
transcriptional transactivation activity of BRCA1 R1699Q in
the 293T cell line relative to pathogenic variant R1699W at the
same residue, and then initiated large-scale genetic studies to
assess if this intermediate function might translate to the
lower risk of breast and ovarian cancer in families for R1699Q
compared with R1699W.
METHODS
Conﬁrmation of transcriptional transactivation activity
Using methods previously described,8 we ﬁrst compared tran-
scriptional transactivation activity of BRCA1 R1699Q in the
293T cell line with that of pathogenic variant, R1699W, at the
same residue, and also to pathogenic control, A1708E, and con-
ﬁrmed our original ﬁndings that this variant displayed inter-
mediate function compared with wild-type sequence and
known pathogenic TAD variants (see supplementary ﬁgure S2).
Genetic analyses
With ethical approval from the relevant institutional review
boards, we then initiated large-scale genetic studies to assess if
this intermediate function might translate to the risk of breast
and ovarian cancer in families. Informed consent was obtained
from all participants. Through collaboration facilitated in part
by the ENIGMA consortium,26 we ascertained sufﬁcient infor-
mation from multiple clinical cancer genetics centres around
the world (table 1) to compare family history and risk proﬁles
of families in which the R1699Q variant had been identiﬁed,
with families with the known pathogenic mutation R1699Wat
the same residue. For an additional reference group, we also col-
lected a set of pedigrees that had been clinically tested for
BRCA1 and BRCA2 mutations from the same centres within
the same time frame as the R1699Q and R1699W families, but
for which no pathogenic mutation or any other unclassiﬁed
variant had been found (BRCA-X). The time frame was deter-
mined by the centres to ensure that a similar criterion for
testing was used. The proband in each instance was deﬁned as
the individual initially screened for BRCA1/2 mutations.
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Family history analysis
As a measure of how each family ﬁt the characteristics of a BRCA1
mutation-positive family, we used the Breast and Ovarian Analysis
of Disease Incidence and Carrier Estimation Algorithm
(BOADICEA) risk-prediction algorithm27–30 to calculate the prob-
ability that the proband from each family was a carrier of a BRCA1
mutation based on the pedigree structure and the phenotypes of
individuals in the pedigree. BOADICEA uses a full pedigree likeli-
hood approach, and incorporates ages at diagnosis of breast and
ovarian cancer, presence of pancreatic and prostate cancer, the age
at last follow-up for unaffected individuals, and the year of birth
to account for cohort effects in penetrance. The model estimates
the simultaneous effects of the high-risk genes BRCA1 and BRCA2
using the age-speciﬁc penetrance estimates derived from 22
population-based studies,17 while allowing for unknown genetic
effects that explain the residual familial clustering of breast cancer.
The residual familial clustering is explained by a polygenic compo-
nent with variance that decreases linearly with age.
The estimated probabilities of the proband carrying a patho-
genic BRCA1 mutation based on the BOADICEA prediction
model, Bi, were then transformed in order to better ﬁt a
Gaussian distribution using a logit transformation bi= logit(Bi)
=ln(Bi/(1−Bi), so that standard statistical methods could be
used. For each centre that contributed R1699Q/W families, we
calculated the mean and SD of the probabilities calculated for
the BRCA-X families from this centre. This distribution was
used to create z-scores as Zij= (bij−Xj)/Sj, where bij is the logit
of the BOADICEA-predicted probability of a BRCA1 mutation
in the ith BRCA-X family in the jth centre, Xj and Sj are the
sample mean and SD of the logit-transformed Bi from the jth
centre. For families with the sequence variants of interest,
R1699Q and R1699W, these Zij thus represent the position of
family histories of probands carrying an R1699Q or R1699W
variant within the distribution of families tested negative for
BRCA1/2 mutations in the same centres and time frame.
Letting ZQi be the standardised logit score of the ith R1699Q
family- and ZWi represent the corresponding score for the ith
R1699W family, and assuming further that the ZQi and ZWi are
Normally distributed with means μQ and μW and variances σ2Q
and σ2W respectively, these scores can then be used to test the
following two hypotheses:
1. The family histories of R1699Q probands are more
BRCA1-like than those of matched BRCA-X. That is, we test
the null hypothesis μQ= 0 versus the alternative μQ>0 with
a one-sample t test. Rejection of the null hypothesis indi-
cates that the R1699Q families have proband/family histor-
ies more compatible with a pathogenic BRCA1 mutation
than the centre-matched BRCA-X families.
2. The family histories of R1699Q are less ‘BRCA1-like’ than
those of R1699W mutations. This is tested by a two-sample
t test of the null hypothesis μQ= μW against the one-sided
alternative μQ< μW.
If both these null hypotheses are rejected, this indicates that
R1699Q variants are, in some sense, intermediate in terms of
their BRCA1 family history proﬁle compared with BRCA-X and
BRCA1 R1699W families.
Segregation analyses
Risk was analysed more directly through analysis of cosegrega-
tion of the R1699Q/W genotypes in the relatives of probands
presenting with R1699Q/W variants.31 Analyses included 30
R1699Q informative families with 111 total tested individuals
and 19 R1699W families with 80 tested individuals. Risks were
estimated by examining the likelihood of the genotypes of the
family members (both, women affected with breast or ovarian
cancer, and healthy women) as a function of BRCA1 penetrance,
conditional on the proband’s genotype and all pedigree pheno-
types. The conditioning is needed to account for the fact that
families were ascertained on the basis of the cancer phenotypes
in the entire family, and the fact that the proband carried the
variant. In this situation, most information about penetrance
derives from the distribution of variant genotypes among
unaffected women. Because there was insufﬁcient additional
genotyping in these families to reliably estimate age-speciﬁc risk
ratios for each age group, we examined the risk associated with
the R1699Q/W variants relative to those associated with the
‘average pathogenic BRCA1 mutation’, as found in much larger
studies of predominantly truncating mutations.17 In these ana-
lyses, the age-speciﬁc HR (by decade) was assumed to be a con-
stant multiple of the estimate of Antoniou et al,17 with
cumulative penetrances re-estimated at each trial value of the
multiplier. This allowed for a similar pattern of age-speciﬁc
effects, as in BRCA1, but only required estimation of a single par-
ameter. We also repeated the analyses allowing for separate pene-
trance multipliers for breast cancer and ovarian cancer to allow
for the possibility that the functional effects of R1699Q or
R1699W might be more relevant to cancer risk for one but not
both these cancers. We varied the multiplier of the assumed
standard penetrance of BRCA1 from 0.05 to 2, in increments of
0.01, in order to ﬁnd the value that maximised the likelihood of
the observed data (and to obtain CIs). If under a particular
model, a given value of the penetrance implied risks of cancer in
carriers lower in a given age group than in non-carriers, these
were constrained to be the same as the non-carrier rates.
The analysis of penetrance was done using the LINKAGE
package of programs32 to calculate pedigree likelihoods, and the
other statistical analyses were performed using STATA V.11.0
(StatCorp, College Station, Texas, USA).
RESULTS
Table 2 shows the results of the analyses comparing family
history scores of probands from R1699Q families, R1699W
families, and families with no BRCA1 pathogenic mutation. Of
note is the ordered progression of the BOADICEA raw scores
showing clear differences between all three groups of families,
Table 1 Number of families included in the family history and
penetrance analyses
Group
#
Sites*
BRCA-X R1699Q R1699W
Family
history
Family
history Penetrance
Family
history Penetrance
The
Netherlands
and Belgium
8 42 15 5 11 4
Germany 13 39 5 1 13 8
France 6 4 5 3 2 1
Spain 1 28 0 0 1 0
Denmark 2 30 10 4 0 0
Mayo clinic,
USA
1 8 7 5 0 0
Sweden 3 14 14 5 5 5
Ohio, USA 1 8 1 1 0 0
Australia 3 44 6 2 0 0
Pennsylvania,
USA
1 2 1 1 0 0
UK 4 24 4 2 2 1
South Africa 1 0 1 1 0 0
Total 243 68 30 34 19
*Number of individual clinic sites for each contributing country or region.
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and the tests of signiﬁcance between groups. The Z-scores for
R1699Q (adjusted for the mean and SD of the BRCA-X families
from the same centres) were signiﬁcantly greater than 0
(p=0.0004), indicating that carriers of the R1699Q variant
have more ‘BRCA1-like’ family histories than families that test
negative for both genes, and that they have some of the charac-
teristics of family history (eg, ovarian cancer) of BRCA1.
However, they are also clearly less ‘BRCA1-like’ than family his-
tories of probands carrying the previously classiﬁed pathogenic
R1699W mutation (p<0.00001).
Although the above analyses indicate that families carrying
R1699Q are different in terms of their personal and family
history from both BRCA-X families, and families carrying the
R1699W variant, these analyses do not directly address the
question of cancer risks conferred by these mutations. They
also do not provide a level of evidence that the variant is patho-
genic, as in the typical assessment of cosegregation within the
framework of the multifactorial model.1 33 Segregation analyses
were thus undertaken. For R1699W, the maximum likelihood
estimate of the relative proportion of the standard BRCA1 pene-
trance was 0.24 (95% CI 0.06 to 1.10), which was not signiﬁ-
cantly different from 1.0 (LR X12= 3.44; p=0.06). The odds in
favour of pathogenicity at this value of the penetrance multi-
plier were 314 100 : 1. When we allowed the possibility that
there were different multipliers for breast and ovarian cancer,
the estimates were 0.11 for breast cancer and 2.35 for ovarian
cancer, with corresponding odds of 2 420 000 : 1 in favour of
pathogenicity. The LR test provided some evidence for differ-
ence from a single value (X12=4.08; p=0.043) and for a differ-
ence from standard penetrance (X22=7.53; p=0.023).
For R1699Q, the maximum likelihood estimate of the pene-
trance multiplier parameter was 0.20 (95% CI 0.09 to 0.45), was
signiﬁcantly reduced compared with the standard model
(X12=14.2; p=0.0002). The odds in favour of pathogenicity were
6226 : 1 for R1699Q at this value of the multiplier, whereas, they
were only 5 : 1 under the standard model. In contrast with
R1699W, allowing separate multipliers for breast and ovarian
cancer did not result in a big difference in likelihood, with esti-
mated parameters of 0.18 for breast cancer and 0.30 for ovarian
cancer (odds of 6787:1), which was not signiﬁcantly different
from a single value of 0.20 (p=0.7) for breast and ovarian cancer.
Clearly, there is a reduced penetrance for this variant, com-
pared with the standard penetrance of BRCA1 as estimated by
Antoniou et al.17 To represent these estimated parameters in
terms of absolute risks which are perhaps more clinically
relevant, we can translate the penetrance multipliers into age-
speciﬁc relative risks of breast and ovarian cancer, and use these
to obtain cumulative risks of breast and/or ovarian cancer by
age, based on the age-speciﬁc relative risks in Antoniou et al.17
Figure 1 shows the predicted cumulative risks of developing
either breast or ovarian cancer based on the maximum likeli-
hood parameter estimates of the breast and ovarian relative risk
multiplier parameters for R1699Q and R1699W, compared with
the standard model and population rates. Similar ﬁgures for
breast cancer risk and ovarian cancer risk, individually, are pro-
vided in the supplementary ﬁgure S3. If our model is correct,
the risk of breast or ovarian cancer to age 70 is 24% (95% CI
10% to 40%) for carriers of BRCA1 R1699Q, and 58% (95% CI
7% to 72%) for carriers of BRCA1 R1699W, assuming the best
ﬁtting model of separate risk multipliers for breast and ovarian
cancers. This compares with 4.6% for women in the general
population, and 68% for the carriers of an average pathogenic
mutation. The risks for R1699Q are higher than that conferred
by family history alone, but still lower than those conferred by
BRCA2 and PALB2 mutations.
DISCUSSION
Although we have presented results of analyses examining risk,
our goal was not to estimate penetrance per se, but rather to
compare these two speciﬁc variants with the penetrance of the
‘average’ BRCA1 mutation (the vast majority of which are trun-
cating), both in terms of family histories of probands carrying
these variants and in terms of cosegregation of the variants
within families. Here we provide, for the ﬁrst time, signiﬁcant
evidence that a BRCA1 variant can be associated with reduced
risks of breast cancer compared with the ‘average’ pathogenic
mutation. It is of particular relevance and consequence for future
studies, since the variant R1699Q was selected for study due to
its behaviour in a variety of functional assays. Depending on the
assay, this missense variant has demonstrated either wild-type
function, abrogated function akin to known pathogenic muta-
tions, or functional activity intermediate between that observed
for wild-type BRCA1 and known truncating pathogenic and mis-
sense pathogenic mutations.
Figure 1 Cumulative risk of breast or ovarian cancer by age,
assuming the best ﬁtting models of penetrance for R1699Q (dotted line)
and R1699W (dashed line). The corresponding curves for the standard
penetrance (solid line) and for the general population (dash-dotted line)
are also shown.
Table 2 Analysis of family history scores
Group Number of families* Mean BOADICEA score†
Z-scores‡
Mean SE
BRCA-X 243 0.085 0.0 0.06
R1699Q 67 0.12 0.48 0.14
R1699W 34 0.36 1.81 0.20
H0: Q=0 t=3.51, 66 df, p=0.0004
H0: Q=W t=−5.5, 99 df, p=1.3×10−7
*Analysis includes 67 families in which the proband carried a R1699Q variant and for
which there was at least one matching BRCA-X family, and the 34 matching families in
which the proband had a R1699W variant. One R1699Q family was excluded because
there was no BRCA-X family available for comparison. For another R1699Q family with
only a single matched BRCA-X family, the SD could not be determined, so the average SD
across all centres was used for analysis. Families were matched by country, as shown in
table 1.
†All BOADICEA scores represent ‘pre-test’ calculations based on family history
information only. Score ranges were as follows: Q: 0.0006 to 0.88; W: 0.0026 to 0.97;
X: 0.0002 to 0.92.
‡See text for definition of Z-scores.
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Interestingly, there was also evidence that the R1699W
variant was associated with signiﬁcantly lower breast cancer
risk and a markedly increased risk of ovarian cancer. We recog-
nise that the estimation of breast and ovarian cancer parameters,
separately, is somewhat difﬁcult given the necessity of condi-
tioning the data on all pedigree phenotypes, but the results,
nevertheless, raise the question that differences in risk of breast
versus ovarian cancer may be a characteristic of some missense
mutations in the BRCT repeat domains. In this regard, we note
that in the 34 R1699W families, there were an average of 2.24
breast cancers and 1.48 ovarian cancers, while in the 68 R1699Q
families, there were 2.35 breast cancers and 0.85 ovarian cancers
per family, consistent with the higher estimated risk of ovarian
cancer in these families. Further study of a large number of such
variants will be necessary to address such an intriguing possibil-
ity that would have clear clinical implications.
Using the standard multifactorial model, the posterior prob-
ability for R1699Q is calculated to be 0.79 from the available
data, namely: prior probability of pathogenicity of 0.66 based
on the A-GVGD class C3523; segregation odds of 5:1 in favour
of pathogenicity from this study of 30 families; LRs from
Easton et al11 of 8:1 against pathogenicity for family history,
and 3:1 in favour of pathogenicity for co-occurrence data. That
is, using the model developed based on the characteristics of
BRCA1 pathogenic mutations of ‘average’ penetrance, R1699Q
would be classiﬁed as International Agency for Research on
Cancer (IARC) Class 3 ‘uncertain’.
Our conclusive ﬁnding that BRCA1 c.5096G>A R1699Q can be
shown to have both intermediate functional deﬁciency in several
assays, and is associated with breast and ovarian cancer risk at sig-
niﬁcantly lower levels than truncating BRCA1 mutations, has a
number of consequences. Our ﬁndings suggest that results from a
battery of functional assays may highlight other variants with
intermediate or equivocal results for investigation as potential
moderate risk variants. Indeed, the variant BRCA1 A1708V
showed abrogated centrosome ampliﬁcation, but normal nuclear
foci formation and trypsin sensitivity equivocal results from a
series of functional assays in our original report,8 and is a candidate
for further investigation as a potential moderate risk variant.
If this observation of intermediate function translating to
intermediate risk is a general ﬁnding, it is likely that there will
be a subset of variants that are difﬁcult to classify using the
standard multifactorial likelihood approaches that are based on
comparing data for a particular variant under the hypothesis
that it is a fully penetrant pathogenic BRCA1 mutation, against
the hypothesis that it is neutral, or of no clinical signiﬁcance,
with respect to risk. As shown for the R1699Q variant with
more families available for analysis than will likely be achieved
for most other rare variants, the standard cosegregation analysis
yielded odds of only 5:1 in favour of the variant being patho-
genic compared with the >6000:1 odds when a lower pene-
trance was allowed. Further, and more importantly, we must
now face the question of how these women should be coun-
selled in terms of cancer risk and the management of that risk.
We do not propose that counselling be any different for
R1699W, although results from the two parameter analyses
suggest that particular attention should perhaps be paid to
ovarian cancer for this known pathogenic variant. We empha-
sise, however, that the CI are wide, particularly for cancer site-
speciﬁc risks, and future studies are necessary to conﬁrm the
markedly increased ovarian cancer risk observed in our dataset.
While there is certainly signiﬁcant evidence that R1699Q car-
riers are at increased risk over population rates, this risk is
markedly lower than that observed for the average BRCA1
mutation. The ﬁndings presented here are likely to provide
impetus for research studies considering approaches to clinical
management of patients with cancer risks intermediate to
those conferred by BRCA1/2 mutations, and those from family
history alone. In the case of R1699Q, counselling could be
similar to that for other moderate-penetrance genes such as
PALB2, CHEK2 and RAD51C, although that may change if
ovarian cancer screening improves given the increased rate of
ovarian cancer over the general population. In all these cases,
the incorporation of the now 30+ common breast cancer sus-
ceptibility alleles into comprehensive risk prediction models
will be of great value in allowing women and their providers to
make informed management decisions. In addition, it would be
interesting to speciﬁcally explore if BRCA1 haplotypes altering
promoter activity,34 35 or potentially altering 30 untranslated
region (UTR) microRNA binding,36 inﬂuence the level of func-
tion of R1699Q in vivo, and explain in part the variable presen-
tation of families.
In summary, we provide evidence that a BRCA1 variant demon-
strating equivocal functional deﬁciency across multiple assays is
associated with intermediate risk of breast and ovarian cancer,
highlighting challenges for risk modelling and clinical management
of patients of this and other potential moderate-risk variants.
Author afﬁliations
1Division of Genetics and Population Health, Queensland Institute of Medical
Research, Brisbane, Queensland, Australia
2School of Medicine, University of Queensland, Brisbane, Queensland, Australia
3Department of Dermatology, University of Utah School of Medicine, Salt Lake City,
Utah, USA
4School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane,
Queensland, Australia
5Peter MacCallum Cancer Institute, Melbourne, Victoria 3000, Australia
6Department of Clinical Genetics, Center for Human and Clinical Genetics, Leiden
University Medical Center, Leiden, The Netherlands
7Department of Medical Genetics, University Medical Center Utrecht, Utrecht,
The Netherlands
8Department of Clinical Genetics, Erasmus MC, University Medical Centre,
Rotterdam, The Netherlands
9See Appendix for full list of ENIGMA collaborators contributing to this study,
operating within and outside of country consortia
10Dutch Belgium UV Consortium, Co-ordinator F.B. Hogervorst, The Netherlands
Cancer Institute, Amsterdam, The Netherlands
11Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm,
Sweden
12Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University,
Uppsala, Sweden
13Department of Gynaecology and Obstetrics, Centre of Familial Breast and Ovarian
Cancer and Centre for Molecular Medicine Cologne, University of Cologne, Cologne,
Germany
14Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig,
Leipzig, Germany
15Department of Gynaecology and Obstetrics, Technical University of Munich, Munich,
Germany
16Institut Curie, Hôpital René Huguenin, Service d'Oncogénétique, U735 INSERM,
Saint-Cloud, France
17Unite Mixte de Genetique Constitutionnelle des Cancers Frequents, Hospices Civils
de Lyon/Centre Leon Berard, Lyon, France
18INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en
Cancérologie de Lyon, Lyon, France
19French COVAR group collaborators co-ordinator Rosette Lidereau, Institut Curie,
Hôpital René Huguenin, Service d'Oncogénétique, U735 INSERM—Saint-Cloud,
France
20Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester,
Minnesota, USA
21Center for Genomic Medicine, Rigshospitalet, Copenhagen University hospital,
Copenhagen, Denmark
22Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
23Faculty of Medicine, University of Southampton, Southampton University Hospital
NHS Trust MP824, Southampton, UK
24Hereditary Cancer Clinic, Prince of Wales Hospital, Randwick, Australia
25Spanish National Cancer Centre, Madrid, Spain
J Med Genet 2012;49:525–532. doi:10.1136/jmedgenet-2012-101037 529
Cancer genetics
group.bmj.com on September 5, 2017 - Published by http://jmg.bmj.com/Downloaded from 
26Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
27Division of Human Cancer Genetics, Departments of Internal Medicine and Molecular
Virology, Immunology and Medical Genetics, OSU Comprehensive Cancer Center, The
Ohio State University, Columbus, Ohio, USA
28Department of Genetics, University of Pretoria, Hatﬁeld, South Africa
29Åke Borg, Department of Oncology, Lund University, Lund, Sweden
30Department of Human Genetics, Center for Human and Clinical Genetics, Leiden
University Medical Center, Leiden, The Netherlands
31Huntsman Cancer Institute, Salt Lake City, Utah, USA
Acknowledgements We thank the many families who participated in this study.
This work is supported by the efforts of laboratory and clinical staff from many
centres around the world. In particular, we would like to acknowledge the efforts of
the individuals named in appendix A for their contribution to this speciﬁc study.
kConFaB thanks Heather Thorne, Eveline Niedermayr, kConFab research nurses and
staff, heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study
for their contributions to kConFab, and the many families who contribute to kConFab.
Contributors All authors made a signiﬁcant contribution to data collection, data
analysis, writing and critical assessment of this study. Speciﬁcally: DEG and ABS
were responsible for study concept and design. DEG performed the statistical
analyses. DEG, ABS and MPGV wrote the manuscript. PJW, SH and BT were
responsible for data collection and management. CJVA, AAKM, MGEMA, RKS, CE,
AM, SC, OS, RL, FJC, LG, TVOH, MT, DME, KT, JB, SMD, AET, EJVT, BW, AB and
MPGV provided the family data analysed in this manuscript; MAB and CP performed
functional analyses, and SC performed structural protein modelling. All authors have
approved the ﬁnal draft submitted.
Funding This work was supported in part by project grants from The National Health
and Medical Research Council (NHMRC) to ABS. ABS is supported by an NHMRC
Senior Research Fellowship. kConFab is supported by grants from the National Breast
Cancer Foundation, the NHMRC and by the Queensland Cancer Fund, the Cancer
Councils of New South Wales, Victoria, Tasmania and South Australia, and the
Cancer Foundation of Western Australia. The kConFab Clinical Follow Up Study was
funded by NHMRC grants (145684 and 288704). BJF is supported by the Canadian
Institutes of Health Research Team Grant in Familial Risks of Breast Cancer
CRN-87521. AL thanks the Swedish Cancer Society for support. The work of the
German Consortium GC-HBOC is supported by a grant of the German Cancer Aid
(grant 107364, RKS) and by the Centre for Molecular Medicine Cologne, Cologne,
Germany (RKS, BW). The French Consortium thanks the Association d’Aide à la
Recherche Cancérologique de Saint Cloud (ARCs) and the Ligue 92 contre le Cancer
for their ﬁnancial support. FJC and DEG are supported by NIH grant CA116167, an
NIH Recovery Act supplement (CA116167Z), and an NIH Specialised Programme of
Research Excellence (SPORE) in Breast Cancer (CA116201). LG is supported by a
Komen Race for the Cure Fellowship. Research by TvOH was supported by the NEYE
Foundation. SMD is supported by funding from the Komen Foundation for the Cure.
Ohio State University CCG is supported by the OSU Comprehensive Cancer Center
(AET). EJVR is funded by grants from the Cancer Association of South Africa. The
research coordinated by MPGV was supported by Dutch Cancer Society grants
2001-2471 and 2006-3677. DEG is supported by NIH grant CA116167. Coordination
of ENIGMA is funded by The National Institutes of Health Recovery Act supplement
award (CA116167Z).
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
APPENDIX
Appendix A ENIGMA collaborators (excluding those named in the author list)
Dutch Belgium UV Consortium
Frans B Hogervorst The Netherlands Cancer Institute, Amsterdam, NL (Coordinating centre)
Rogier A Oldenburg Erasmus Medical Center, Rotterdam, NL
Juul T Wijnen, Peter Devilee Leiden University Medical Center, Leiden, NL
Rob B van der Luijt University Medical Center Utrecht, Utrecht, NL
Johan JP Gille, Muriel A Adank VU University Medical Center, Amsterdam, NL
Encarna B Gomez Garcia, Marinus J Blok University Hospital Maastricht, Maastricht, NL
Jan C Oosterwijk, AH van der Hout University Medical Center Groningen University, NL
Genevieve Michils, Eric Legius University of Leuven, Leuven, Belgium
Erik Teugels, Jacques de Grève Familial Cancer Clinic, UZ Brussel, Brussels, Belgium
German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC)
Norbert Arnold Department of Gynaecology and Obstetrics, University Hospital of Schleswig-Holstein, Christian-Albrechts Campus
Kiel, Kiel, Germany
Helmut Deisler Department of Obstetrics and Gynaecology, University of Ulm, Ulm, Germany
Dorothea Gadzicki Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany
Andrea Gehrig Centre of Familial Breast and Ovarian Cancer, Department of Medical Genetics, Institute of Human Genetics,
University Würzburg, Germany
Wolfram Heinritz Institute of Human Genetics, University of Leipzig, Leipzig, Germany
Karin Kast Department of Gynaecology and Obstetrics, University Hospital, Technical University of Dresden, Dresden, Germany
Dieter Niederacher Department of Gynaecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf,
Germany
Sabine Preisler-Adams Institute of Human Genetics, University of Münster, Vesaliusweg, Germany
Christian Sutter Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany
Raymonda Varon-Mateeva Institute of Human Genetics, Campus Virchov Klinikum, Charite Berlin, Germany
Bernhard H Weber Institute of Human Genetics, University of Regensburg, Regensburg, Germany
French BRCA GGC consortium
Nicolas Sévenet, Françoise Bonnet, Michel Longy Institut Bergonié—Bordeaux
Agnès Hardouin, Dominique Vaur, Sophie Krieger Centre François Baclesse—Caen
Nancy Uhrhammer, Yves-Jean Bignon Centre Jean Perrin—Clermont-Ferrand
Jean-Philippe Peyrat, Françoise Revillion, Joëlle Fournier Centre Oscar Lambret—Lille
Sylvie Mazoyer Centre de Recherche en Cancérologie de Lyon—Lyon
Mélanie Léone Hospices Civils de Lyon and Centre Léon Bérard—Lyon
Hagay Sobol, Tetsuro Noguchi, Violaine Bourdon, Audrey
Remenieras
Institut Paoli-Calmettes—Marseille
Jean-Marc Rey Laboratoire de Biologie Cellulaire et Hormonale (CHU Arnaud de Villeneuve) —Montpellier
Myriam Bronner, Joanna Sokolowska-Gillois, Philippe
Jonveaux
CHU de Nancy-Brabois—Vandœuvre-lès-Nancy
Capucine Delnatte CHU—Institut de Biologie—Hôtel Dieu—Nantes
Continued
530 J Med Genet 2012;49:525–532. doi:10.1136/jmedgenet-2012-101037
Cancer genetics
group.bmj.com on September 5, 2017 - Published by http://jmg.bmj.com/Downloaded from 
REFERENCES
1. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ.
Integrated evaluation of DNA sequence variants of unknown clinical signiﬁcance:
application to BRCA1 and BRCA2. Am J Hum Genet 2004;75:535–44.
2. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS,
Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV. Sequence variant
classiﬁcation and reporting: recommendations for improving the interpretation of
cancer susceptibility genetic test results. Hum Mutat 2008;29:1282–91.
3. Whiley PJ, Guidugli L, Walker LC, Healey S, Thompson BA, Lakhani SR, Da Silva
LM, Tavtigian SV, Goldgar DE, Brown MA, Couch FJ, Spurdle AB. Splicing and
multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identiﬁes
clinically signiﬁcant splicing aberrations up to 12 nucleotides from the intron/exon
boundary. Hum Mutat 2011;32:678–87.
4. Walker LC, Whiley PJ, Couch FJ, Farrugia DJ, Healey S, Eccles DM, Lin F, Butler
SA, Goff SA, Thompson BA, Lakhani SR, Da Silva LM, Tavtigian SV, Goldgar DE,
Brown MA, Spurdle AB. Detection of splicing aberrations caused by BRCA1 and
BRCA2 sequence variants encoding missense substitutions: implications for
prediction of pathogenicity. Hum Mutat 2010;31:E1484–505.
5. Thomassen M, Blanco A, Montagna M, Hansen TV, Pedersen IS, Gutierrez-Enriquez
S, Menendez M, Fachal L, Santamarina M, Steffensen AY, Jonson L, Agata S,
Whiley P, Tognazzo S, Tornero E, Jensen UB, Balmana J, Kruse TA, Goldgar DE,
Lazaro C, Diez O, Spurdle AB, Vega A. Characterization of BRCA1 and BRCA2
splicing variants: a collaborative report by ENIGMA consortium members. Breast
Cancer Res Treat 2012;132:1009–23.
6. Spurdle AB, Lakhani SR, Healey S, Parry S, Da Silva LM, Brinkworth R, Hopper JL,
Brown MA, Babikyan D, Chenevix-Trench G, Tavtigian SV, Goldgar DE. Clinical
classiﬁcation of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin
proﬁles and evolutionary analysis—a report from the kConFab Investigators. J Clin
Oncol 2008;26:1657–63.
7. Spurdle AB, Lakhani SR, Da Silva LM, Balleine RL, Goldgar DE. Bayes analysis
provides evidence of pathogenicity for the BRCA1 c.135-1G>T (IVS3-1) and BRCA2
c.7977-1G>C (IVS17-1) variants displaying in vitro splicing results of equivocal
clinical signiﬁcance. Hum Mutat 2010;31:E1141–5.
8. Lovelock PK, Spurdle AB, Mok MT, Farrugia DJ, Lakhani SR, Healey S, Arnold S,
Buchanan D, Couch FJ, Henderson BR, Goldgar DE, Tavtigian SV, Chenevix-Trench G,
Brown MA. Identiﬁcation of BRCA1 missense substitutions that confer partial
functional activity: potential moderate risk variants? Breast Cancer Res 2007;9:R82.
9. Lovelock PK, Healey S, Au W, Sum EY, Tesoriero A, Wong EM, Hinson S,
Brinkworth R, Bekessy A, Diez O, Izatt L, Solomon E, Jenkins M, Renard H, Hopper
J, Waring P, Tavtigian SV, Goldgar D, Lindeman GJ, Visvader JE, Couch FJ,
Henderson BR, Southey M, Chenevix-Trench G, Spurdle AB, Brown MA. Genetic,
functional, and histopathological evaluation of two C-terminal BRCA1 missense
variants. J Med Genet 2006;43:74–83.
10. Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R,
Deffenbaugh AM, Burbidge LA, Pruss D, Judkins T, Scholl T, Bekessy A, Marsh A,
Lovelock P, Wong M, Tesoriero A, Renard H, Southey M, Hopper JL, Yannoukakos K,
Brown M, Easton D, Tavtigian SV, Goldgar D, Spurdle AB. Genetic and
histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown
clinical signiﬁcance. Cancer Res 2006;66:2019–27.
11. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian
SV, Monteiro AN, Iversen ES, Couch FJ, Goldgar DE. A systematic genetic
assessment of 1,433 sequence variants of unknown clinical signiﬁcance in the
BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet
2007;81:873–83.
12. Sweet K, Senter L, Pilarski R, Wei L, Toland AE. Characterization of BRCA1
ring ﬁnger variants of uncertain signiﬁcance. Breast Cancer Res Treat
2010;119:737–43.
13. Spearman AD, Sweet K, Zhou XP, McLennan J, Couch FJ, Toland AE. Clinically
applicable models to characterize BRCA1 and BRCA2 variants of uncertain
signiﬁcance. J Clin Oncol 2008;26:5393–400.
14. Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D,
Zharkikh A, Thomas A. Comprehensive statistical study of 452 BRCA1 missense
Appendix A Continued
Florence Coulet Groupe hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie,
Laboratoire d’Oncogénétique et Angiogénétique moléculaire—Paris
Laurent Castera, Virginie Caux-Moncoutier, Claude Houdayer,
Dominique Stoppa-Lyonnet
Institut Curie—Paris
Chantal Delvincourt, Marie-Claude Gorisse CHU et Institut Jean Godinot—Reims
Ivan Bièche, Cédrick Lefol, Etienne Rouleau Institut Curie—Hôpital René Huguenin, Service d’Oncogénétique—Saint Cloud
Joseph Abecassis, Danièle Muller Centre Paul Strauss—Strasbourg
Christine Toulas Institut Claudius Régaud—Toulouse
Marine Guillaud-Bataille, Brigitte Bressac-de Paillerets Institut Gustave Roussy—Villejuif
ENIGMA collaborators operating outside of a country consortium
Richard Barber West Midlands Regional Genetics Laboratory, Birmingham Women’s NHS, Foundation Trust, Edgbaston,
Birmingham, UK
Tina Bedenham Oxford Molecular Genetic Laboratory, Oxford University Hospital NHS Trust, The Churchill Hospital, Oxford, UK
Lucy Burgess West Midlands Regional Clinical Genetics Service, Birmingham, UK
Joanna Campbell DNA laboratory, Guy’s Hospital, London, UK
Jackie Cook Sheffield Clinical Genetics Service, Sheffield Children’s Hospital, Western Bank, Sheffield, UK
Andrew Devereau NGRL Manchester, Genetic Medicine, St Mary ’s Hospital, Manchester, UK
Bent Ejlertsen Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Mike Fields Familial Cancer Service, Royal North Shore Hospital, Sydney, Australia
Anne-Marie Gerdes Department of Clinical Genetics, Rigs hospital and Copenhagen University, Denmark
Elizabeth Johnston West Midlands Regional Genetics Laboratory, Birmingham Women’s NHS, Foundation Trust, Edgbaston,
Birmingham, UK
Torben A Kruse Department of Clinical Genetics, Odense University Hospital, Denmark
Anita Luharia West Midlands Regional Genetics Laboratory, Birmingham Women’s NHS, Foundation Trust, Edgbaston,
Birmingham, UK
Carole Mckeown West Midlands Regional Clinical Genetics Service, Birmingham, UK
Kate Nathanson Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
Finn C Nielsen Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Leigha Senter Clinical Cancer Genetics Program, Division of Human Genetics, Department of Internal Medicine, OSU
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
Barbara Stayner Oxford Regional Genetics Service, Oxford, UK
Kevin Sweet Clinical Cancer Genetics Program, Division of Human Genetics, Department of Internal Medicine, OSU
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
Simon Thomas Wessex Regional Genetics Laboratory, UK
Yvonne Wallis West Midlands Regional Genetics Laboratory, Birmingham Women’s NHS, Foundation Trust, Edgbaston,
Birmingham, UK
Sally Watts Clinical Genetics Department, Guy ’s Hospital, London, UK
J Med Genet 2012;49:525–532. doi:10.1136/jmedgenet-2012-101037 531
Cancer genetics
group.bmj.com on September 5, 2017 - Published by http://jmg.bmj.com/Downloaded from 
substitutions with classiﬁcation of eight recurrent substitutions as neutral. J Med
Genet 2006;43:295–305.
15. Farrugia DJ, Agarwal MK, Pankratz VS, Deffenbaugh AM, Pruss D, Frye C, Wadum
L, Johnson K, Mentlick J, Tavtigian SV, Goldgar DE, Couch FJ. Functional assays for
classiﬁcation of BRCA2 variants of uncertain signiﬁcance. Cancer Res
2008;68:3523–31.
16. Vallee MP, Francy TC, Judkins MK, Babikyan D, Lesueur F, Gammon A, Goldgar DE,
Couch FJ, Tavtigian SV. Classiﬁcation of missense substitutions in the BRCA genes:
a database dedicated to Ex-UVs. Hum Mutat 2012;33:22–8.
17. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N,
Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang
N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H,
Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D,
Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian
cancer associated with BRCA1 or BRCA2 mutations detected in case Series
unselected for family history: a combined analysis of 22 studies. Am J Hum Genet
2003;72:1117–30.
18. Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT,
Brondum-Nielsen K, Gerdes AM, Moller P, Kristoffersson U, Olsson H, Borg A,
Monteiro AN. Functional analysis of BRCA1 C-terminal missense mutations identiﬁed
in breast and ovarian cancer families. Hum Mol Genet 2001;10:353–60.
19. Lee MS, Green R, Marsillac SM, Coquelle N, Williams RS, Yeung T, Foo D, Hau DD,
Hui B, Monteiro AN, Glover JN. Comprehensive analysis of missense variations in
the BRCT domain of BRCA1 by structural and functional assays. Cancer Res
2010;70:4880–90.
20. Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L, Haines DC, Basik M,
Mai P, Poggi E, Isaacs C, Looi LM, Mun KS, Greene MH, Byers SW, Teo SH, Deng
CX, Sharan SK. Tumor suppressor BRCA1 epigenetically controls oncogenic
microRNA-155. Nat Med 2011;17:1275–82.
21. Williams RS, Green R, Glover JN. Crystal structure of the BRCT repeat region from
the breast cancer-associated protein BRCA1. Nat Struct Biol 2001;8:838–42.
22. Coquelle N, Green R, Glover JN. Impact of BRCA1 BRCT domain missense
substitutions on phosphopeptide recognition. Biochemistry 2011;50:4579–89.
23. Tavtigian SV, Byrnes GB, Goldgar DE, Thomas A. Classiﬁcation of rare missense
substitutions, using risk surfaces, with genetic- and molecular-epidemiology
applications. Hum Mutat 2008;29:1342–54.
24. Mohammadi L, Vreeswijk MP, Oldenburg R, van den Ouweland A, Oosterwijk JC,
van der Hout AH, Hoogerbrugge N, Ligtenberg M, Ausems MG, van der Luijt RB,
Dommering CJ, Gille JJ, Verhoef S, Hogervorst FB, van Os TA, Gomez Garcia E, Blok
MJ, Wijnen JT, Helmer Q, Devilee P, van Asperen CJ, van Houwelingen HC. A
simple method for co-segregation analysis to evaluate the pathogenicity of
unclassiﬁed variants; BRCA1 and BRCA2 as an example. BMC Cancer 2009;9:211.
25. Gomez Garcia EB, Oosterwijk JC, Timmermans M, van Asperen CJ, Hogervorst
FB, Hoogerbrugge N, Oldenburg R, Verhoef S, Dommering CJ, Ausems MG, van Os
TA, van der Hout AH, Ligtenberg M, van den Ouweland A, van der Luijt RB, Wijnen
JT, Gille JJ, Lindsey PJ, Devilee P, Blok MJ, Vreeswijk MP. A method to assess the
clinical signiﬁcance of unclassiﬁed variants in the BRCA1 and BRCA2 genes based
on cancer family history. Breast Cancer Res 2009;11:R8.
26. Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL,
Radice P, Stoppa-Lyonnet D, Tavtigian S, Wappenschmidt B, Couch FJ, Goldgar DE.
ENIGMA-Evidence-based network for the interpretation of germline mutant alleles:
an international initiative to evaluate risk and clinical signiﬁcance associated with
sequence variation in BRCA1 and BRCA2 genes. Hum Mutat 2012;33:2–7.
27. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA,
Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Pasini B,
Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E,
Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola
H, Nevanlinna H, Pharoah PD, Easton DF. The BOADICEA model of genetic
susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer
2008;98:1457–66.
28. Mavaddat N, Rebbeck TR, Lakhani SR, Easton DF, Antoniou AC. Incorporating
tumour pathology information into breast cancer risk prediction algorithms. Breast
Cancer Res 2010;12:R28.
29. Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic
susceptibility to breast and ovarian cancer. Br J Cancer 2004;91:1580–90.
30. Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles R, Shanley S, Pichert
G, Izatt L, Rose S, Douglas F, Eccles D, Morrison PJ, Scott J, Zimmern RL, Easton
DF, Pharoah PD. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation:
validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system
using data from UK genetics clinics. J Med Genet 2008;45:425–31.
31. Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, Terry MB, Daly
MJ, Buys SM, Southey MC, Andrulis I, John EM, Khanna KK, Hopper JL, Oefner PJ,
Lakhani S, Chenevix-Trench G. Rare variants in the ATM gene and risk of breast
cancer. Breast Cancer Res 2011;13:R73.
32. Lathrop GM, Lalouel JM, Julier C, Ott J. Strategies for multilocus linkage analysis
in humans. Proc Natl Acad Sci USA 1984;81:3443–6.
33. Goldgar DE, Easton DF, Byrnes GB, Spurdle AB, Iversen ES, Greenblatt MS. Genetic
evidence and integration of various data sources for classifying uncertain variants
into a single model. Hum Mutat 2008;29:1265–72.
34. Chan KY, Liu W, Long JR, Yip SP, Chan SY, Shu XO, Chua DT, Cheung AN, Ching JC,
Cai H, Au GK, Chan M, Foo W, Ngan HY, Gao YT, Ngan ES, Garcia-Barcelo MM,
Zheng W, Khoo US. Functional polymorphisms in the BRCA1 promoter inﬂuence
transcription and are associated with decreased risk for breast cancer in Chinese
women. J Med Genet 2009;46:32–9.
35. Cox DG, Simard J, Sinnett D, Hamdi Y, Soucy P, Ouimet M, Barjhoux L, Verny-Pierre
C, McGuffog L, Healey S, Szabo C, Greene MH, Mai PL, Andrulis IL, Thomassen M,
Gerdes AM, Caligo MA, Friedman E, Laitman Y, Kaufman B, Paluch SS, Borg A,
Karlsson P, Askmalm MS, Bustinza GB, Nathanson KL, Domchek SM, Rebbeck TR,
Benitez J, Hamann U, Rookus MA, van den Ouweland AM, Ausems MG, Aalfs CM,
van Asperen CJ, Devilee P, Gille HJ, Peock S, Frost D, Evans DG, Eeles R, Izatt L,
Adlard J, Paterson J, Eason J, Godwin AK, Remon MA, Moncoutier V,
Gauthier-Villars M, Lasset C, Giraud S, Hardouin A, Berthet P, Sobol H, Eisinger F,
Bressac de Paillerets B, Caron O, Delnatte C, Goldgar D, Miron A, Ozcelik H, Buys S,
Southey MC, Terry MB, Singer CF, Dressler AC, Tea MK, Hansen TV, Johannsson O,
Piedmonte M, Rodriguez GC, Basil JB, Blank S, Toland AE, Montagna M, Isaacs C,
Blanco I, Gayther SA, Moysich KB, Schmutzler RK, Wappenschmidt B, Engel C,
Meindl A, Ditsch N, Arnold N, Niederacher D, Sutter C, Gadzicki D, Fiebig B, Caldes
T, Laframboise R, Nevanlinna H, Chen X, Beesley J, Spurdle AB, Neuhausen SL, Ding
YC, Couch FJ, Wang X, Peterlongo P, Manoukian S, Bernard L, Radice P, Easton DF,
Chenevix-Trench G, Antoniou AC, Stoppa-Lyonnet D, Mazoyer S, Sinilnikova OM.
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in
BRCA1 mutation carriers. Hum Mol Genet 2011;20:4732–47.
36. Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K,
van den Ouweland A, Zelterman D, Slack FJ, Kidd KK, Weidhaas JB. Rare BRCA1
haplotypes including 30UTR SNPs associated with breast cancer risk. Cell Cycle
2011;10:90–9.
532 J Med Genet 2012;49:525–532. doi:10.1136/jmedgenet-2012-101037
Cancer genetics
group.bmj.com on September 5, 2017 - Published by http://jmg.bmj.com/Downloaded from 
intermediate breast and ovarian cancer risk
ambiguous functional abrogation confers 
BRCA1 R1699Q variant displaying
and David E Goldgar
Rensburg, Barbara Wappenschmidt, Åke Borg, Maaike P G Vreeswijk
Javier Benitez, Susan M Domchek, Amanda E Toland, Elizabeth J Van 
Overeem Hansen, Mads Thomassen, Diana M Eccles, Kathy Tucker,
group collaborators, Fergus J Couch, Lucia Guidugli, Thomas van 
Sandrine Caputo, Olga M Sinilnikova, Rosette Lidereau, French COVAR
Meindl, German Consortium of Hereditary Breast and Ovarian Cancer, 
Lindblom, Maritta H Pigg, Rita K Schmutzler, Christoph Engel, Alfons
Ans M W van den Ouweland, Dutch Belgium UV Consortium, Annika 
Van Asperen, Margreet G E M Ausems, Anna A Kattentidt-Mouravieva,
Sue Healey, Melissa A Brown, Christopher Pettigrew, kConFab, Christi J 
Amanda B Spurdle, Phillip J Whiley, Bryony Thompson, Bingjian Feng,
doi: 10.1136/jmedgenet-2012-101037
2012 49: 525-532 J Med Genet 
 http://jmg.bmj.com/content/49/8/525
Updated information and services can be found at: 
These include:
Material
Supplementary
 .DC1
http://jmg.bmj.com/content/suppl/2012/08/12/jmedgenet-2012-101037
Supplementary material can be found at: 
References
 #BIBLhttp://jmg.bmj.com/content/49/8/525
This article cites 36 articles, 10 of which you can access for free at: 
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (239)Breast cancer
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on September 5, 2017 - Published by http://jmg.bmj.com/Downloaded from 
